清脆的
计算生物学
生物
癌症免疫疗法
基因组编辑
免疫疗法
免疫系统
遗传学
基因
作者
Dan Liú,Xuan Zhao,Anqun Tang,Xiyue Xu,Shuci Liu,Li Zha,Wei Ma,Junnian Zheng,Ming Shi
标识
DOI:10.1016/j.bbcan.2020.188378
摘要
CRISPR/Cas-based genetic perturbation screens have emerged as powerful tools for large-scale identification of new targets for cancer immunotherapy. Various strategies of CRISPR screen have been used for immune-oncology (IO) target discovery. The genomic sequences targeted by CRISPR/Cas system range from coding sequences to non-coding RNA/DNA, including miRNAs, LncRNAs, circRNAs, promoters, and enhancers, which may be potential targets for future pharmacological and therapeutic interventions. Rapid progresses have been witnessed in finding novel targets for enhancing tumor antigen presentation, sensitizing of tumor cells to immune-mediated cytotoxicity, and reinvigorating tumor-specific T cells by using CRISPR technologies. In combination with other strategies, the detailed characteristics of the targets for immunotherapy have been obtained by CRISPR screen. In this review, we present an overview of recent progresses in the development of CRISPR-based screens for IO target identification and discuss the challenges and possible solutions in this rapidly growing field.
科研通智能强力驱动
Strongly Powered by AbleSci AI